Forest Laboratories gains European approval for Colobreathe dry powder inhaler
The product is indicated for cystic fibrosis patients aged six years and older with chronic lung infection caused by P. aeruginosa. An open-label active comparator study comparing the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.